Shanghai Xuerong Bio-Technology Co Ltd (300511) - Total Assets

Latest as of June 2025: CN¥3.61 Billion CNY ≈ $527.99 Million USD

Based on the latest financial reports, Shanghai Xuerong Bio-Technology Co Ltd (300511) holds total assets worth CN¥3.61 Billion CNY (≈ $527.99 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Shanghai Xuerong Bio-Technology Co Ltd service its debt to assess how comfortably operating cash covers total debt obligations.

Shanghai Xuerong Bio-Technology Co Ltd - Total Assets Trend (2012–2024)

This chart illustrates how Shanghai Xuerong Bio-Technology Co Ltd's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Shanghai Xuerong Bio-Technology Co Ltd for net asset value and shareholders' equity analysis.

Shanghai Xuerong Bio-Technology Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Shanghai Xuerong Bio-Technology Co Ltd's total assets of CN¥3.61 Billion consist of 14.2% current assets and 85.8% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 4.4%
Accounts Receivable CN¥31.39 Million 0.8%
Inventory CN¥325.34 Million 8.4%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥299.63 Million 7.8%
Goodwill CN¥0.00 0.0%

Asset Composition Trend (2012–2024)

This chart illustrates how Shanghai Xuerong Bio-Technology Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Shanghai Xuerong Bio-Technology Co Ltd.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Shanghai Xuerong Bio-Technology Co Ltd's current assets represent 14.2% of total assets in 2024, an increase from 0.0% in 2012.
  • Cash Position: Cash and equivalents constituted 4.4% of total assets in 2024, up from 3.6% in 2012.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, a decrease from 12.0% in 2012.
  • Asset Diversification: The largest asset category is inventory at 8.4% of total assets.

Shanghai Xuerong Bio-Technology Co Ltd Competitors by Total Assets

Key competitors of Shanghai Xuerong Bio-Technology Co Ltd based on total assets are shown below.

Company Country Total Assets
Sildarvinnslan Hf.
IC:SVN
Iceland Ikr1.08 Billion
Fujian Wanchen Biotechnology Co. Ltd
SHE:300972
China CN¥10.76 Billion
Yunnan Shennong Agricultural Industry Group Co Ltd
SHG:605296
China CN¥7.16 Billion
Austevoll Seafood ASA
OL:AUSS
Norway Nkr52.37 Billion
United Plantations Bhd
KLSE:2089
Malaysia RM3.47 Billion
Shandong Yisheng Livestock & Poultry Breeding Co Ltd
SHE:002458
China CN¥7.22 Billion
Fujian Sunner Development Co Ltd
SHE:002299
China CN¥23.50 Billion
Great-Sun Foods Co Ltd
SHG:603336
China CN¥1.78 Billion

Shanghai Xuerong Bio-Technology Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 0.31 0.53 1.10
Quick Ratio 0.08 0.27 0.76
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥-1.05 Billion CN¥-780.55 Million CN¥112.17 Million

Shanghai Xuerong Bio-Technology Co Ltd - Advanced Valuation Insights

This section examines the relationship between Shanghai Xuerong Bio-Technology Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 3.08
Latest Market Cap to Assets Ratio 0.12
Asset Growth Rate (YoY) -16.2%
Total Assets CN¥3.85 Billion
Market Capitalization $477.32 Million USD

Valuation Analysis

Below Book Valuation: The market values Shanghai Xuerong Bio-Technology Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.

Significant Asset Reduction: Shanghai Xuerong Bio-Technology Co Ltd's assets decreased by 16.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for Shanghai Xuerong Bio-Technology Co Ltd (2012–2024)

The table below shows the annual total assets of Shanghai Xuerong Bio-Technology Co Ltd from 2012 to 2024.

Year Total Assets Change
2024-12-31 CN¥3.85 Billion
≈ $564.04 Million
-16.24%
2023-12-31 CN¥4.60 Billion
≈ $673.44 Million
+13.02%
2022-12-31 CN¥4.07 Billion
≈ $595.87 Million
-6.18%
2021-12-31 CN¥4.34 Billion
≈ $635.10 Million
-4.92%
2020-12-31 CN¥4.56 Billion
≈ $667.95 Million
+18.81%
2019-12-31 CN¥3.84 Billion
≈ $562.18 Million
-1.30%
2018-12-31 CN¥3.89 Billion
≈ $569.60 Million
+1.46%
2017-12-31 CN¥3.84 Billion
≈ $561.38 Million
+55.91%
2016-12-31 CN¥2.46 Billion
≈ $360.06 Million
+38.64%
2015-12-31 CN¥1.77 Billion
≈ $259.70 Million
+14.60%
2014-12-31 CN¥1.55 Billion
≈ $226.62 Million
+5.82%
2013-12-31 CN¥1.46 Billion
≈ $214.15 Million
+3.79%
2012-12-31 CN¥1.41 Billion
≈ $206.32 Million
--

About Shanghai Xuerong Bio-Technology Co Ltd

SHE:300511 China Farm Products
Market Cap
$477.32 Million
CN¥3.26 Billion CNY
Market Cap Rank
#12236 Global
#3430 in China
Share Price
CN¥5.09
Change (1 day)
-2.49%
52-Week Range
CN¥5.03 - CN¥8.24
All Time High
CN¥25.74
About

Shanghai Xuerong Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research and development, cultivation and sale of fresh edible mushrooms in the People's Republic of China. It offers enoki mushrooms; shiitake mushrooms, including oyster mushrooms, white jade mushrooms and seafood mushrooms; king oyster mushrooms; and velvet mushrooms, as well as Pleurotus eryngii and Flammu… Read more